

# In vivo functions of the proprotein convertase PC5/6 during mouse development: Gdf11 is a likely substrate

Rachid Essalmani, Ahmed Zaid, Jadwiga Marcinkiewicz, Ann Chamberland, Antonella Pasquato, Nabil G. Seidah, and Annik Prat\*

Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, QC, Canada H2W 1R7

Edited by Donald F. Steiner, University of Chicago, Chicago, IL, and approved January 31, 2008 (received for review October 3, 2007)

The proprotein convertase PC5/6 cleaves protein precursors after basic amino acids and is essential for implantation in CD1/129/Sv/C57BL/6 mixed-background mice. Conditional inactivation of *Pcsk5* in the epiblast but not in the extraembryonic tissue bypassed early embryonic lethality but resulted in death at birth. PC5/6-deficient embryos exhibited Gdf11-related phenotypes such as altered anteroposterior patterning with extra vertebrae and lack of tail and kidney agenesis. They also exhibited Gdf11-independent phenotypes, such as a smaller size, multiple hemorrhages, collapsed alveoli, and retarded ossification. *In situ* hybridization revealed overlapping PC5/6 and Gdf11 mRNA expression patterns. *In vitro* and *ex vivo* analyses showed that the selectivity of PC5/6 for Gdf11 essentially resides in the presence of a P1' Asn in the RSRR↓N cleavage motif. This work identifies Gdf11 as a likely *in vivo* specific substrate of PC5/6 and opens the way to the identification of other key substrates of this convertase.

Furin-like | Meox2-cre | Pcsk5

In mammals, seven proprotein convertases (PCs) cleave protein precursors at basic sites during their transit through the secretory pathway and/or at the cell surface (1, 2). PC-mediated cleavages contribute to generating active products (hormones, neuropeptides, growth factors, receptors, and viral glycoproteins). In some cases, they lead to substrate inactivation (endothelial and lipoprotein lipases) (3, 4). Among the seven basic amino acid-specific PCs, furin, PC5/6, PACE4, and PC7 are ubiquitous or widely distributed, although they exhibit characteristic patterns of expression (5). However, in *ex vivo* coexpression experiments, a given substrate is often cleaved by more than one of these four secretory proteases, which renders difficult the identification of their specific substrates *in vivo*.

PC5/6 is encoded as two splicing isoforms. PC5/6A contains 21 exons and, in PC5/6B, the 21st exon is replaced by 18 additional exons (6, 7). PC5/6A exhibits a C-terminal Cys-rich domain (CRD). In PC5/6B, this domain is extended and followed by a transmembrane domain and a cytosolic tail. Although PC5/6B can be shed and thus released from the membrane, the soluble PC5/6A can interact with cell surface proteoglycans because of its CRD (8). PC5/6B transcripts dominate in the intestine and kidney, whereas PC5/6A is the major isoform in most other tissues assessed, except in the liver, where the transcripts are expressed in equivalent amounts (9).

Because of the redundancy observed *ex vivo* among the basic amino acid-specific PCs, it is important to define their *in vivo* properties. Knockouts (KOs) of the PCs (10, 11) resulted in strong phenotypes, except for PC7, and demonstrated that furin and PC5/6 are essential. Inactivation of the furin gene, *Pcsk3* (PC subtilisin kexin type 3), resulted in embryonic dysmorphism with the absence of axial rotation and heart looping and led to embryonic death around embryonic day (E)11 (12). Inactivation of the PACE4 gene, *Pcsk6*, resulted in 25% lethality before E15.5. PACE4<sup>-/-</sup> embryos frequently exhibit anterior trunca-

tions and/or specific laterality defects, such as cyclopia, mislocalization of organs and cardiac malformations (13). Our group showed that *Pcsk5* inactivation, by removal of exon 4 ( $\Delta 4$ ) that encodes the catalytic Asp, led to embryonic lethality between E4.5 and E7.5 (9).

To bypass the PC5/6<sup>-/-</sup> embryonic lethality at the implantation stage and to better define the functions of PC5/6, we decided to develop a conditional approach for *Pcsk5* inactivation. *In situ* hybridization studies indicated that PC5/6 was not significantly expressed in the fetus itself before E7.5 (14). We thus hypothesized that PC5/6 was essential in embryonic cell lineages that give rise to the extraembryonic tissue, which ensures the survival of the embryo in the uterine environment. We show here that using the *Meox2-cre* transgene (Tg), which directs Cre expression in the epiblast at E5 but not in extraembryonic lineages, we were able to bypass early embryonic lethality and identify an essential role of PC5/6 in the regulation of the anteroposterior axial patterning, through the processing of the growth and differentiation factor 11 (Gdf11).

## Results

**PC5/6 Is Expressed in the Extraembryonic Lineage.** The inability of mutant embryos to go through the implantation stage often resides in deficiencies in the extraembryonic lineages (15). We thus assessed the PC5/6 mRNA expression in extraembryonic cells at early stages by *in situ* hybridization (Fig. 1). The analysis of embryos *in utero* revealed that, at E4.5, PC5/6 was strongly expressed in decidual cells around the implantation site but not in the luminal epithelium of the uterus or the embryo [data not shown (16)]. At E6.5, PC5/6 expression was detected in large nuclei typical of the trophoblast giant cells, as reported (17). No labeling was observed in the embryo proper. We thus hypothesized that PC5/6 was essential in the extraembryonic tissue.

**Epiblast-Specific KO of *Pcsk5*.** Because, by *in situ* hybridization, PC5/6 was not strongly expressed at early stages in the embryo proper (data not shown), we decided to perform an epiblast-specific KO of PC5/6 in an attempt to discover PC5/6-related phenotypes later in development or at adulthood. A *Pcsk5* conditional allele was generated by framing the proximal promoter and exon 1 with *loxP* sites [supporting information (SI) Fig. S1]. In the presence of the *CMV-cre* Tg, *Pcsk5* <sup>$\Delta 1/+$</sup>  mice were

Author contributions: R.E., A.Z., N.G.S., and A. Prat designed research; R.E., A.Z., J.M., A.C., A. Pasquato, and A. Prat performed research; J.M. contributed new reagents/analytic tools; R.E., N.G.S., and A. Prat analyzed data; and N.G.S. and A. Prat wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Freely available online through the PNAS open access option.

\*To whom correspondence should be addressed. E-mail: prata@ircm.qc.ca.

This article contains supporting information online at [www.pnas.org/cgi/content/full/0709428105/DCSupplemental](http://www.pnas.org/cgi/content/full/0709428105/DCSupplemental).

© 2008 by The National Academy of Sciences of the USA





12-mer peptide encompassing the predicted S1 of Gdf11 with the four constitutive PCs, furin, PACE4, PC5/6, and PC7 (2) revealed that PC5/6 cleaves the WT sequence better than PACE4, and that furin and PC7 do not process this peptide. The presence of an Asn at the P1' position (first residue after the cleavage site) is rather unique in PC substrates (2). To assess its importance, a N297D peptide was synthesized, in which Asn was substituted to Asp, which is known to favor furin cleavage (21) and to be present in the S1 processing site of Gdf8, the closest member to Gdf11 in the TGF $\beta$ -like protein family with 90% of identity within their TGF $\beta$ -like domain. This resulted in the cleavage at S1 by all four convertases and thus in the loss of PC5/6 selectivity (Fig. 6), although PC5/6 remained the fastest-cleaving enzyme (data not shown). We next transiently coexpressed in HEK293 cells mouse Gdf11, tagged with a FLAG epitope at the C terminus, with either PC5/6A, PC5/6B, furin, PC7, or PACE4. Western blot analysis of the media with a FLAG Ab showed that only PC5/6A and PC5/6B efficiently processed proGdf11 into the  $\approx$ 15-kDa mature Gdf11 (Fig. 6). Evidence that processing by PC5/6 occurred at the canonical S1 site **R**<sub>293</sub>**xxR**<sub>296</sub> motif (2) was obtained by the mutagenizing the P1 (R296A) or P4 (R293A) Arg in Gdf11 cDNA. This completely prevented cleavage by PC5/6A or PC5/6B (Fig. 6).

## Discussion

We have shown that PC5/6<sup>-/-</sup> embryos die at the implantation stage (9). We report here that the generation of an epiblast-specific KO, in which the proximal promoter and exon 1 are excised by Cre expressed from the *Meox2* locus, allowed us to bypass early embryonic death but led to death at birth. The rescue of early embryonic death by normal expression of PC5/6 in extraembryonic lineages demonstrated that PC5/6 is essential in these cells. This is in agreement with the high expression of PC5/6 mRNA in cells lining the inner side of the maternal embryonic junction at E6.5 (Fig. 1 and ref. 17) and at E9 in rat (22). The key substrate(s) that necessitate PC5/6 cleavage remain to be identified.

At E18.5, cKO embryos exhibited skeleton alterations and multiple organ defects, including kidney agenesis, collapsed lung alveoli, and multiple hemorrhages. The absence of tail and presence of extra thoracic and lumbar segments in cKO embryos were also observed in embryos deficient in Gdf11 (19) or its main downstream receptors, activin type IIB (23) and ALK5 (24). Gdf11 is a secreted member of the TGF $\beta$  superfamily that participates in the establishment of the anterior–posterior axis by controlling the spatiotemporal expression of *Hox* genes. In the absence of Gdf11, the expression pattern of some *Hoxc* genes expanded posteriorly or was caudally displaced (19, 25, 26). Because the activity of Gdf11 but not that of its receptors depends on a PC-mediated cleavage, our data strongly suggest that Gdf11 is a substrate of PC5/6. Gdf11 is a unique secretory protein that specifies the segmental characteristics of vertebrae, likely through a gradual signaling to target cells (19). The combination of the extracellular activities of the membrane-bound PC5/6B and secreted PC5/6A may modulate the gradient of active Gdf11, critical for its patterning functions.

However, PC5/6 cKO and Gdf11<sup>-/-</sup> skeleton defects are not completely identical. Alterations in the patterning of the axial skeleton of Gdf11<sup>-/-</sup> embryos are more severe with an average of 18 ribs, including 10 vertebrosteral ones, instead of 16–17 ribs, including eight or nine vertebrosteral ones in most cKO embryos. In addition, Gdf11 heterozygotes have an additional thoracic segment not observed in PC5/6 ones. We believe that the PC5/6 cKO is quasicomplete in phenotypically mutant embryos: (i) assessment of the presence of *flox* alleles in various tissues of the same embryos failed to detect significant mosaicism [no signal by PCR on genomic DNA (data not shown) and, depending on tissues, 0–3% of residual expression by RT-PCR

(Table S2)]; and (ii) bilateral kidney agenesis seems as severe, if not more, in PC5/6- than in Gdf11-deficient embryos [ $>$  90% vs.  $\approx$ 60% (27), respectively]. A more likely explanation for the observed skeletal differences is that, in the absence of PC5/6, another PC, possibly PACE4 (Fig. 6), may exert a minor but not negligible contribution to Gdf11 processing. Finally, the observed phenotypic differences may also be due to different genetic backgrounds, known to affect dramatically some phenotypes (28, 29). As for Gdf11 KO (19), we obtained 129Sv-derived ES cells that were injected in C57BL/6 blastocysts. However, in our case, *in vivo* excision of the *neo* cassette (*flox*) and exon 1 region ( $\Delta$ 1) required flipase and Cre (*CMV-cre* and *Meox2-cre*) expressing strains of mixed 129S4/Sv, C57BL/6, and SJL backgrounds. Parallel to this work, we backcrossed our mixed background strains carrying *flox* or  $\Delta$ 1 alleles nine generations to C57BL/6. Very recently, we were contacted by Shoumo Bhattacharya and colleagues, who isolated a PC5/6 mutant strain obtained by *N*-ethyl *N*-nitrosourea (ENU) mutagenesis and backcrossed to C3H/HeH for several generations (personal communication). When homozygous for this mutation, the embryos exhibited the same phenotypes as our cKO ones. Their ability to go through implantation, possibly because of a PC5/6 residual activity, prompted us to check for the viability of  $\Delta$ 1/ $\Delta$ 1 embryos in an almost pure C57BL/6 background. To our surprise, we detected  $\Delta$ 1/ $\Delta$ 1 embryos in a first litter at E10.5. Further studies will be required to phenotype them at E18.5. If they are as viable as cKO embryos, their characterization will help us understand the PC5/6 contribution to organogenesis and will open the door to the design of new cKOs.

Aside from the axial patterning phenotype, cKO embryos exhibited skeletal phenotypes not reported for Gdf11<sup>-/-</sup> embryos, such as smaller size, severe retardation of ossification, incomplete and asymmetric fusion of the sternum, and abnormal symphysis of pubic bones. Some of these phenotypes were associated with the lack of platelet-derived growth factor A or B (PDGF A/B) receptors (30) and/or their target genes (31) and the BMP-potentiator crossveinless 2 (32). Because PC5/6 can process PDGFs (33), it is possible that the observed phenotypes are related to the lack of processing of these and/or other TGF $\beta$ -like factors, such as BMP4 (20) and Lefty (34). Although the precise cause of death of the cKO pups at birth is unknown, our observations suggest it resides in their inability to breathe. Collapsed alveoli (Fig. 4) are a hallmark of lungs deficient in surfactant. The latter is released into the alveoli by type II pneumocytes to reduce the surface tension of the fluid that lines the alveolar walls. Whether PC5/6 is required in this process needs further investigation. The respiratory distress of the newborns may also be due to hernias in the diaphragm (data not shown). Death may also be due to the absence of kidneys or hemorrhages (Fig. 4). The latter may be related to the absence of PDGF B processing by PC5/6 (33), resulting in fragile blood vessels, as reported in PDGFR $\beta$ -deficient mice (35).

Gene inactivation of the other broadly expressed basic amino acid-specific PCs revealed that furin and PACE4 also play important roles in development, likely through cleavage of a network of TGF $\beta$  family members (12, 13, 36). However, although PACE4, whose absence leads to 75% of viability, is in most cases accessory, the absence of Furin (12) or PC5/6 during development results in embryonic death. The cKO approach presented here led to the identification of an *in vivo*-specific substrate of PC5/6, namely Gdf11. Whether this enzyme–substrate pair is the result of a quasiabsence of other PCs in Gdf11-expressing cells or its poor processing by other PCs is not yet clear. On the one hand, our *in vitro* data indicate that the presence of the P1' Asn contributes to make Gdf11 a favorite substrate of PC5/6 (Fig. 6). In agreement, the negative regulation of muscle growth by Gdf8, whose S1 site differs from the Gdf11 one by the presence of a P1' Asp, does not seem to be affected

in cKO embryos. *Gdf8*<sup>-/-</sup> mice are indeed larger and exhibit a 2- to 3-fold increase in their muscle mass. However, *Gdf11* may not be exclusively cleaved by PC5/6; a gross examination of cKO pancreata failed to reveal the reported 2-fold reduction of the exocrine pancreas in *Gdf11*<sup>-/-</sup> embryos (37). However, this phenotype may also be modulated by the genetic background.

Because no antibodies sensitive and specific enough to detect endogenous levels of *Gdf11* or *Gdf8* are available, our multiple attempts to evaluate the extent of processing of *Gdf11* and *Gdf8* in embryo extracts were unsuccessful. Interestingly, database searches revealed that, among mouse secretory proteins, the RSRRN motif is found only in *Gdf11*.

Our work showed that PC5/6 is vital in the extraembryonic tissue and epiblast. The respective roles of the evolutionary conserved (38) PC5/6A and PC5/6B isoforms remain to be elucidated. The overall more severe phenotype of cKO embryos that die immediately at birth compared with the *Gdf11*<sup>-/-</sup> ones that survive up to 24 h should lead to the identification of other key substrates of PC5/6.

## Methods

**Construction of the Targeting Vector.** Using the Canadian Institutes of Health Research Genomic Resource Facility, a 129/Sv mouse genomic BAC library was screened by using a *Pcsk5* exon 1 probe (E1; 5'-GCGAAGCGGCGAAGCGTCCG vs. 5'-TCCTACGTTGATGAATCCGTAC). The 5' and 3' arms of the targeting vector were obtained by digestion of the 56L22-positive clone by using *KpnI* or *BamHI* and *XbaI*, respectively, and subcloned in a pUC19 plasmid whose polylinker exhibits *EcoRI*, *Clal*, *KpnI*, *Ascl*, *PacI*, *BamHI*, *Sall*, *Clal*, and *HindIII* sites (Fig. S1). The 5' *loxP* site consisting of two annealed oligonucleotides was inserted into a unique *AvrII* site of the 5' arm. A 1.9-kb fragment containing the 3' *loxP* site and a PGK-*neo* cassette flanked with two *frt* sites was subcloned into *Ascl* and *PacI* sites. Digestion of the targeting vector with *Clal* released a 12,951-bp fragment, which was purified on an agarose gel and electroporated into R1 ES cells [(129/Sv × 129/Sv-CP)F1 (39)].

**Generation of *Pcsk5* cKO Mice.** Six hundred G418-resistant ES clones were screened for homologous recombination by Southern blot analysis of *StuI*-digested DNA, by using a mixture of 5' A and 3' A external probes (Fig. S1). *StuI* cleaves in the *neo* cassette and upstream and downstream of the 5' A and 3' A probes, respectively. The DNA of the positive clones was further analyzed by using *NheI* or *EcoRI* and the E1 probe. The 4E7 clone revealed a correct insertion of a single copy of the insert at the *Pcsk5* locus. This clone was injected into C57BL/6 blastocysts and transferred to pseudopregnant females to produce chimeras. To eliminate the *neo* cassette, chimeras were mated to expressing the *Flp* recombinase at the ROSA locus or from a Tg under the control of the  $\beta$ -actin promoter, respectively (The Jackson Laboratory). The latter was found to be more efficient. Resulting heterozygous mice for the floxed allele, *Pcsk5*<sup>lox/+</sup>, were crossed to Tg(*CMV-cre*) mice (40) to delete exon 1 (*Pcsk5*<sup>Δ1/+</sup>). The knockin mice expressing Cre at the *Meox2* locus were from The Jackson Laboratory.

**PCR Genotyping of Embryos and Mice.** Embryos and mice were genotyped by PCR by using liver or tail DNA. *WT*, *neo*, *flox*, and  $\Delta 1$  alleles were detected by

using the following primers: *WT*, 5'-GGGATCGGCCAGTAGCCAGACTATACGG vs. 5'-CCGAAGCGGCGAAGCGTCC; *neo*, 5'-GTCCGGTGCCTGAATGAAC vs. 5'-CCGCAAGCTCTTCAGCAAT; *flox*, 5'-CAGAATGGTGTGCTCTGGA vs. 5'-GTATTGGCATTTCCTCAGC; and  $\Delta 1$ , 5'-GGGATCGGCCAGTAGCCAGACTATACGG vs. 5'-CCCATAAAATGATTGGCATTTCCTCAGC.

**Histology.** Tissues were collected in BPS and fixed overnight with Bouin's solution at 4°C, washed in ethanol 70%, and embedded in paraffin. Sections were cut at 4  $\mu$ m thickness and stained with hematoxylin/eosin.

**Skeletal Preparations.** E18.5 embryos were incubated overnight in tap water at room temperature, immersed for 30 sec in water at 65°C, and then skinned, eviscerated, and dehydrated in 90% ethanol for 1 day. After a 3-day incubation in acetone to remove fat, the skeletons were stained for 36 h in 13% acetic acid, 61.3% ethanol, 0.0046% Alcian blue 8GX (ESBE Laboratory), and 0.002% Alizarin red 5 (ICN Biochemical). The skeletons were then transferred into a cleaning solution (1% KOH in 20% glycerol) for 24 h at 37°C, further incubated at room temperature until specimens were completely leached, and stored in a 2:2:1 mix of ethanol, glycerol, and benzyl alcohol.

**In Situ Hybridization.** Twelve-micrometer-thick cryosections of embryos at E9.5, E10.5, or E18.5 were fixed in 4% formaldehyde at 4°C for 1 h. For PC5/6 labeling *in utero*, E6.5 uteri from pregnant females were fixed in 4% formaldehyde overnight at 4°C, embedded in paraffin, and cut into 5- $\mu$ m sections. After deparaffination and rehydration, these or the above cryosections were hybridized with mouse PC5/6 antisense and control sense cRNA probe as described (9, 41). To generate a mGdf11 cRNA probe, a cDNA segment covering the sequence encoding amino acids 67–404 was amplified by using sense 5'-GCAGCACAGCCGCGAGCTG and antisense 5'-GATACCGTGGAG-CAGCCACATCGATCCAC oligonucleotides and subcloned in pDrive (Qiagen).

**Whole-Mount in Situ Hybridization.** This was performed as described (42) except that hybridization with above probes was performed at 70°C and that 2 mM Levamisole (Sigma) was added during the incubation with anti-digoxigenin-alkaline phosphatase Ab (Roche) and subsequent washes.

**In Vitro Assays, Transfection, and Western Blot Analysis.** The 12-mer peptides were incubated *in vitro* overnight with 2 units of purified PCs [2 pmol amino methyl coumarin (AMC) released per minute from the peptide Pyr-RTKR-MCA) (43)], in 2 mM CaCl<sub>2</sub> and 25 mM Tris-Mes, pH 7.5, in a volume of 100  $\mu$ l. The products were separated by RP-HPLC on a Varian C<sub>18</sub> column (5  $\mu$ m, 100 Å, 4.5 × 250 mm), and MS confirmed that cleavage took place exclusively after Arg<sup>296</sup>. HEK293 cells were grown in DMEM containing 10% heat-inactivated FCS (Canadian Life Technologies) at 37°C in 5% CO<sub>2</sub>. Cells (1 × 10<sup>6</sup> plated on 35-mm plates) were transfected with plain or recombinant vectors (0.6  $\mu$ g) using Effectene (Qiagen). The medium was replaced 12 h after transfection by a serum-free medium, and cells were grown for an additional 24 h. Media were analyzed by SDS/PAGE, Western blot analysis using the FLAG M2 Ab (1:1,000; Stratagene), and ECL (Amersham Biosciences).

**ACKNOWLEDGMENTS.** We thank Shoumo Bhattacharya for the exchange of our respective manuscripts before submission. We also thank Gaoxiang Ge for the mGdf11 cDNA, Brigitte Mary for secretarial help, Claudia Toulouse for excellent animal care, and Dominic Fillion and Qinzhang Zhu for solid technical assistance. This work was supported by grants from the Canadian Institutes of Health Research (MGP-44363 and Canada Chair no. 20652).

- Steiner DF (1998) The proprotein convertases. *Curr Opin Chem Biol* 2:31–39.
- Seidah NG, Chretien M (1999) Proprotein and prohormone convertases: A family of subtilases generating diverse bioactive polypeptides. *Brain Res* 848:45–62.
- Jin W, et al. (2007) Hepatic proprotein convertases modulate HDL metabolism. *Cell Metab* 6:129–136.
- Seidah NG, Prat A (2007) The proprotein convertases are potential targets in the treatment of dyslipidemia. *J Mol Med* 85:685–696.
- Seidah NG, Day R, Marcinkiewicz M, Chretien M (1998) Precursor convertases: An evolutionary ancient, cell-specific, combinatorial mechanism yielding diverse bioactive peptides and proteins. *Ann NY Acad Sci* 839:9–24.
- Lusson J, et al. (1993) cDNA structure of the mouse and rat subtilisin/kexin-like PC5: A candidate proprotein convertase expressed in endocrine and nonendocrine cells. *Proc Natl Acad Sci USA* 90:6691–6695.
- Nakagawa T, Murakami K, Nakayama K (1993) Identification of an isoform with an extremely large Cys-rich region of PC6, a Kex2-like processing endoprotease. *FEBS Lett* 327:165–171.
- Nour N, et al. (2005) The cysteine-rich domain of the secreted proprotein convertases PCSA and PACE4 functions as a cell surface anchor and interacts with tissue inhibitors of metalloproteinases. *Mol Biol Cell* 16:5215–5226.
- Essalmani R, et al. (2006) Deletion of the gene encoding proprotein convertase 5/6 causes early embryonic lethality in the mouse. *Mol Cell Biol* 26:354–361.
- Taylor NA, Van de Ven WJ, Creemers JW (2003) Curbing activation: Proprotein convertases in homeostasis and pathology. *FASEB J* 17:1215–1227.
- Scamuffa N, Calvo F, Chretien M, Seidah NG, Khatib AM (2006) Proprotein convertases: Lessons from knockouts. *FASEB J* 20:1954–1963.
- Roebroek AJ, et al. (1998) Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. *Development* 125:4863–4876.
- Constam DB, Robertson EJ (2000) SPC4/PACE4 regulates a TGFbeta signaling network during axis formation. *Genes Dev* 14:1146–1155.
- Constam DB, Calton M, Robertson EJ (1996) SPC4, SPC6, and the novel protease SPC7 are coexpressed with bone morphogenetic proteins at distinct sites during embryogenesis. *J Cell Biol* 134:181–191.
- Rossant J, Cross JC (2001) Placental development: lessons from mouse mutants. *Nat Rev Genet* 2:538–548.
- Nie GY, Li Y, Minoura H, Findlay JK, Salamonsen LA (2003) Specific and transient up-regulation of proprotein convertase 6 at the site of embryo implantation and identification of a unique transcript in mouse uterus during early pregnancy. *Biol Reprod* 68:439–447.

